semaglutide compounding news november 2025 September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns FDA – Partnership for Safe Medicines The FDA has received reports

The pill is likely to be cheaper than the injectables and one (not yet available in Europe) has been shown to help maintain weight loss after coming off injectables

Some expect quick results, eat too little, or dont include enough protein in their diet

This innovative treatment uses high-intensity fractional ultrasound technology to tighten skin, kickstart brand-new collagen production, improve the appearance of cellulite and acne scars, and reduce the appearance of lines and wrinkles

It includes multiple trials studying retatrutide in different populations: TRIUMPH-1 (obesity/overweight without type 2 diabetes, NCT05929066), TRIUMPH-3 (severe obesity + cardiovascular disease, NCT05882045), TRIUMPH-9 (dose-escalation in obesity, NCT07357415), and TRIUMPH-Outcomes (cardiovascular and kidney outcomes in adults with obesity, NCT06383390)

Vendors that provide dosing guides, reconstitution instructions, and storage recommendations demonstrate expertise and investment in their customer base

5 Companies receiving warning letters have 15 working days to respond with a corrective action plan or a justification